secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001439222-24-000117
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end
--------------------------------------------------------------------------------

- PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.
- Net loss $96.1M vs $83.8M YoY; cash, equivalents, marketable securities $645.3M at June 30.
- Phase 3 ENERGIZE-T met primary endpoint in transfusion-dependent thalassemia; sNDA filing planned by end of 2024.
- Announced $905M purchase agreement with Royalty Pharma for vorasidenib royalty; total $1.1B payable upon FDA approval.
- Announced ACTIVATE-KidsT topline data in pediatric PK deficiency; ACTIVATE-Kids enrollment complete, data in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000117/0001439222-24-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000117/agio-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001439222-24-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer